Plain-English translation of NCT07614984 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called , designed to lower lipoprotein(a)—a harmful type of cholesterol that increases heart disease risk. Researchers also want to see if works better when combined with another medication called decanoate, which lowers a different harmful cholesterol called LDL. The study will compare these treatments to placebo (a pill with no active medicine) to see which approach is most effective and safe.
High lipoprotein(a) is a strong risk factor for heart disease and stroke, and current treatments don't adequately lower it in many patients. This trial exists to find out whether this new medication can effectively reduce lipoprotein(a) levels, potentially offering patients a better way to protect their heart health.
You likely qualify if…
You likely don't qualify if…
You will take a daily pill for approximately 12 weeks. Depending on which group you're randomly assigned to, you'll receive either the new medication, an existing medication, both together, or a placebo. You'll visit the study clinic for check-ups and blood tests to measure your cholesterol levels and monitor for any side effects. The researchers will track how well the treatment works and whether it's safe.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
United States